42results about How to "Increase oxygen saturation" patented technology

A versatile, multi-port, intubation-permitting oxygen mask is provided including two diaphragms (nasal and oral) each configured with a continuous, flexible, modifiable membrane from which an instrument-access port may be manually constructed, when and if needed. The novel oxygen mask preferably includes a multiple-inlet port having a standard oxygen tube connector and an interchangeable breathing-therapy device connector, a carbon dioxide sampling port, an exhaust port, and a nose clip. The mask can be worn as a standard oxygen mask during traditional oxygen therapy, yet quickly converted into an intubation mask. The clinician manually perforates the nasal and/or oral diaphragm to create a point and size of entry perfectly matched to the requirements for a variety of procedures that may be performed involving nasally or orally introduced scopes or probes—without disturbing the ongoing benefits of increased oxygen saturation and continuous monitoring of expired gases.

A versatile, intubation-facilitating oxygen mask is provided including at least one diaphragm configured with a continuous, flexible, modifiable membrane from which an instrument-access port may be manually constructed, when and if needed. The novel oxygen mask preferably includes a multiple-inlet port having a standard oxygen tube connector and an interchangeable breathing-therapy device connector, a carbon dioxide sampling port, an exhaust port, and a nose clip. The mask can be worn as a standard oxygen mask during traditional oxygen therapy, yet quickly converted into an intubation mask. The clinician manually perforates the nasal and/or oral membranes of the one or more diaphragms to create a point and size of entry perfectly matched to the requirements for a variety of procedures that may be performed involving nasally or orally introduced scopes or probes—without disturbing the ongoing benefits of increased oxygen saturation and continuous monitoring of expired gases.

A device and a process for controlling a respirator with inclusion of an oxygen saturation value (34) for compensating a device-dependent time response (15), a physiological time response (16) and a measuring method-dependent time response (17) are described. The device-dependent time response (15), the physiological time response (16) and the measuring method-dependent time response (17) are determined in a continuous sequence and a run time of a change in the oxygen concentration from the metering means (9) in the respirator to the patient (4) is determined and taken into account in regulating the oxygen concentration.

The invention discloses a self-foaming cosmetic composition. The self-foaming cosmetic composition is prepared from the ingredients in percentage by mass: 50-99.9% of cosmetic matrix and 0.1-50% of foamer, wherein the foamer is a fluorine containing ether compound, and the cosmetic matrix is prepared from deionized water, alcohols, an aqueous-phase tackifier, a humectant, an anionic surfactant, a zwitterionic surfactant, a non-ionic surfactant, fat and oil, an inorganic salt or macromolecular thickener, an alkaline neutralizing agent, an active ingredient, a preservative and essence. The self-foaming cosmetic composition disclosed by the invention has the advantages that the condition of skin can be obviously improved so as to enable the skin to be tender and bright and smooth wrinkles.

The invention discloses a self-foaming cosmetic composition. The self-foaming cosmetic composition is prepared from the ingredients in percentage by mass: 65-99.5% of cosmetic matrix and 0.5-35% of foamer, wherein the foamer is a fluorine containing ether compound, and the cosmetic matrix is prepared from deionized water, alcohols, an aqueous-phase tackifier, a humectant, an anionic surfactant, a zwitterionic surfactant, a non-ionic surfactant, fat and oil, an inorganic salt or macromolecular thickener, an alkaline neutralizing agent, an active ingredient, a preservative and essence. The self-foaming cosmetic composition disclosed by the invention has the advantages that the condition of skin can be obviously improved so as to enable the skin to be tender and bright and smooth wrinkles.

The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental.

Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and/or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.

A sleep apnoea treatment device comprises a mouthpiece including a vestibular locator and an airway conduit. The vestibular locator is adapted for positioning in the mouth vestibule of a user interposed between the lips and teeth of the user. The vestibular locator is to support the airway conduit in place relative to the user's mouth with the airway conduit extending between the lips of the user whereby the airway conduit maintains fluid communication of the mouth vestibule with ambient air to facilitate the user breathing ambient air through the airway conduit.

The present invention has shown that not all salts of pyruvic acid enhance lung functions or enhance the synthesis of lung surfactants and that certain salts of pyruvic acid with the correct concentrations of calcium, phosphate and magnesium, is are synergistic in their ability to enhance the synthesis of lung surfactants that will enhance lung alveoli functions, while decreasing coughing and lung tightness, and increasing oxygen saturation values to prevent hypoxemia. This patent demonstrates that the sodium pyruvate formula with calcium, phosphate and magnesium was superior over standard sodium pyruvate formula in saline alone in the removal of mucus, reduction of lung or sinus infections, and in reducing drug side effects and congestion. The use of this formula clearly demonstrated that it can be used to produce better efficacy in patients with hypoxemia, with lung and sinus diseases including, asthma, COPD, cystic fibrosis, interstitial lung disease, allergic rhinitis, sinusitis, Alzheimer's, disease, Parkinson's disease, brain trauma, nicotine addiction, sleep apnea, autism, migraine headaches, sleep disorders, lung and sinus infections, cancer therapy with cancer drugs, nicotine addiction, and medications that cause a decrease in lung surfactants.

The present invention relates to methods for treating obstructive sleep apnea (OSA), alleviating a negative OSA symptom, reducing snoring, or improving quality of life in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising pyridostigmine before sleep. Also provided are related medicaments as well as methods for preparing the medicaments.

One or more embodiments of the present invention provide a conversion mask that is quick, safe and cost effective and a method for increasing oxygen saturation and/or arresting a subsequent decline in oxygen saturation, which does not unnecessarily increase costs, require a bulky and uncomfortable mask or disrupt the flow of oxygen and/or care being provided to the patient. In one or more embodiments, the conversion mask has a thin, lightweight non latex plastic shield or tent-like mask designed to convert a nasal cannula to a full oxygen capturing mask. The conversion mask serves to capture oxygen escaping from nasal cannula effectively redirecting it back to the mouth and nose, thereby improving oxygenation and/or arresting a decline in oxygenation of patients, particular those under conscious sedation, deep Propofol anesthesia or post general anesthesia, with low oxygen saturation levels until they can be transferred to next level care.

The invention discloses a peony renewal mask and a preparation method thereof and relates to the technical field of natural plant cosmetics. The peony renewal mask is prepared from raw materials in parts by weight as follows: 5-10 parts of a peony flower extract, 3-6 parts of a peony root extract, 3-6 parts of a radix notoginseng extract, 3-5 parts of sodium hyaluronate, 2-5 parts of glycerin, 1-3parts of sodium carboxymethyl glucan, 1-3 parts of hydroxyethyl cellulose, 2-3 parts of collagen and 65-75 parts of water. All components in the mask interact with one another, so that the mask can improve metabolism of face skin, promote skin microcirculation, increase skin vitality, whiten and moisturize skin, resist winkles, improve skin brightness and delay skin aging, can moisten skin and has certain effects on chloasma, skin aging, wrinkles and dry and dull skin if often used.

An environment friendly method for culturing the spiny sea cucumber in pond without feeding bait features that the contents of the N in nitrate, ammoniacal nitrogen, the N in nitrite and the soluble phosphate in the seawater in pond are controlled respectively to be 80-120 micrograms/L, 100-400 micrograms/L, 70-100 micrograms/L and 15-25 micrograms/L, and the water depth in pond is less than the transparency of said water.

A soil-less plant cultivation substrate, for use in hydroponic or aeroponic plant cultivation, adapts entangled layers of natural wool batting that has been chemically treated with a compound containing thiol to increase its water holding capacity. In the preferred embodiment, the chemical treatment uses thioglycolic acid, such as calcium thioglycolate or ammonium thioglycolate, to increase the wool's solubility and then a neutralizing agent, such as hydrogen peroxide, halts the process. The thiol compound reduces the disulfide bonds of cysteine in the cortex of the wool and the hydrogen peroxide neutralizes the reaction and oxidizes the cysteines back to cystine, although not all disulfide bonds are reformed. The addition of an alkaline modifier is used to moderate or hasten the breaking the disulfide bonds.